U.S. Stock Market Midday Update

AIM ImmunoTech, up 12.10%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

Argenx up 16.20%. Based on recent key news:

1. On August 17, Argenx reported positive results from the Phase III ALKIVIA trial of VYVGART Hytrulo in the field of autoimmune myositis. The drug achieved its primary endpoint at week 52, showing significant clinical improvement compared to placebo, driving the stock price up. Analysts expect peak sales of the drug to reach $3 billion in the IMNM field and $1.7 billion in the DM field, mainly based on its strong efficacy and good safety profile.

2. On August 17, Argenx's Efgartigimod achieved positive results in the Phase III trial for the treatment of autoimmune myositis, with patients showing significant statistical and clinical improvement at week 52. The drug was well-tolerated in the trial, driving the stock price up.

3. On August 17, Argenx announced that its drug Efgartigimod showed early and sustained improvement in the ALKIVIA trial, achieving its primary endpoint, which drove the stock price up. Argenx has an average annual return rate of 25.33% over the past five years.

Amgen up 0.39%. Based on recent key news:

1. On August 17, Barclays raised Amgen's target price from $360 to $380, maintaining a neutral rating. This move reflects market confidence in Amgen's future growth potential, driving the stock price up.

2. On August 17, the global pharmaceutical industry's market value landscape is being reshaped, with Amgen performing well in the competitive fields of immunology and oncology, enhancing investor expectations for its long-term growth, promoting stock price increases.

3. On August 15, market analysis indicated that Amgen was not included in the top five stocks recommended by leading analysts; nevertheless, Amgen still maintains a hold rating, showing market recognition of its stability. The competition in the pharmaceutical industry is intensifying, with uncertain growth points.

AbbVie up 0.27%, with active trading. Based on recent key news:

1. On August 15, Glenview Capital Management increased its stake in AbbVie, showing confidence in the company, which drove the stock price up. According to the latest 13F filing, Glenview Capital Management purchased approximately 149,000 shares of AbbVie.

2. On August 17, market analysis pointed out that although AbbVie is currently rated as "moderate buy," top analysts believe there are five other stocks that are more attractive. This analysis may have some impact on investor sentiment On August 17, AbbVie was reported to have a new blockbuster business emerging, which may enhance market expectations for its future growth and further support its stock price. The pharmaceutical industry has entered a stage of high-quality development.

Stocks ranked at the top of the industry by market capitalization

Gilead Sciences, up 0.38%, with a market capitalization of $172.2 billion, saw increased trading volume and no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation